Actively Recruiting
PBMC as Biomarkers of Diabetic Cardiomyopathy
Led by Hospices Civils de Lyon · Updated on 2026-03-27
175
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Type 2 diabetes (T2D), especially when associated with metabolic syndrome (MS) is at high risk to develop heart failure with preserved ejection fraction (HFpEF) or heart failure with mildly reduced ejection fraction (HFmrEF), and the specific impact of T2D+MS in cardiac function impairment is usually known as "diabetic cardiomyopathy" (DC). Cardiac remodelling (ie hypertrophy) and subtle myocardial dysfunction are highly prevalent in T2D+MS but not specific enough to predict further HFpEF or HFmrEF. Also, current biomarkers can identify but do not predict HFpEF or HFmrEF in T2D patients; Furthermore, specific biomarkers are needed. Peripheral blood mononuclear cells (PBMC) obtained from a peripheral blood sample can provide insights from calcic and inflammatory pathways, and may identify more specific molecular signatures shared between T2D+MS and HFpEF.
CONDITIONS
Official Title
PBMC as Biomarkers of Diabetic Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient attending a scheduled cardiology or endocrinology follow-up visit
- Patient fasting for blood sampling
- Male or female aged 40 to 85 years inclusive
- Patient not opposing participation in this research
- Patient agreeing to the storage of biological samples and to genetic analyses
- Group 1: Patient without T2D or MS and without heart failure coming to a consultation or day hospital for another reason
- Group 2: Patient without T2D or MS and diagnosed with HFpEF or HFmrEF
- Group 3: Patient diagnosed with T2D and MS without heart failure
- Group 4: Patient diagnosed with T2D and MS and diagnosed with HFpEF or HFmrEF
You will not qualify if you...
- History of cardiovascular disease other than HFpEF or HFmrEF, including valvular disease greater than moderate severity, radiation-induced, post-cardiotoxic chemotherapy, amyloidosis
- Acute or ongoing systemic inflammatory or infectious disease
- History of known coronary artery disease
- Uncontrolled hypertension (greater than 160/100 mmHg)
- Pregnant or breastfeeding women
- Persons deprived of liberty by judicial or administrative decision
- Persons undergoing psychiatric care
- Patient under legal protection (guardianship or curatorship)
- Subject participating in another interventional study with an ongoing exclusion period
- Chronic kidney disease with eGFR less than 30 mL/min/1.73 m²
- Group 1: Presence of diabetes or metabolic syndrome, presence of heart failure or other known heart disease
- Group 2: Presence of diabetes or metabolic syndrome, left ventricular ejection fraction (LVEF) less than or equal to 40%
- Group 3: Without type 2 diabetes or presence of other diabetes types, presence of any heart failure
- Group 4: Absence of type 2 diabetes or presence of other diabetes types, LVEF less than or equal to 40%
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hopital Louis Pradel
Bron, France, 69677
Actively Recruiting
Research Team
H
Hélène THIBAULT, PU,PH
CONTACT
J
Julia CANTERINI
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here